Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 32Metastatic Castration-resistant Prostate Cancer 4Kidney Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Carcinoma, Renal Cell 2Urogenital Neoplasms 1Thrombocytopenia 1Renal Insufficiency 1Prostatic Diseases 1Prostate Cancer Metastatic 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Liver Neoplasms 1High-Risk Localized Prostate Cancer 1Glioma 1Glioblastoma 1Genital Neoplasms, Male 1Disease 1Cytopenia 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Hepatocellular 1Carcinoma 1Astrocytoma 1Anemia 1

Interventions

Pluvicto 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone Naive Prostate Cancer × Pluvicto × 1 year × Clear all
NCT04343885 2025-07-11

UpFrontPSMA

Peter MacCallum Cancer Centre, Australia

Phase 2 Active not recruiting
130 enrolled
Genitourinary

Metastatic Hormone Naive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡